{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:02:48Z","timestamp":1779951768005,"version":"3.53.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Almirall Hermal GmbH, Reinbek, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13555-026-01713-1","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T12:51:39Z","timestamp":1774702299000},"page":"2483-2497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tildrakizumab Real-World Experience (T-REX) in Plaque Psoriasis: Meta-Analysis of Four Non-interventional Studies"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-7402","authenticated-orcid":false,"given":"Athanasios","family":"Tsianakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6802-0153","authenticated-orcid":false,"given":"Nina","family":"Magnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afra","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Andersohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8042-7885","authenticated-orcid":false,"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-0486","authenticated-orcid":false,"given":"Dennis","family":"Niebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"4","key":"1713_CR1","first-page":"278","volume":"63","author":"WB Kim","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63(4):278\u201385.","journal-title":"Can Fam Physician"},{"issue":"14","key":"1713_CR2","first-page":"467","volume":"121","author":"U Mrowietz","year":"2024","unstructured":"Mrowietz U, Lauffer F, Sondermann W, Gerdes S, Sewerin P. Psoriasis as a systemic disease. Dtsch Arztebl Int. 2024;121(14):467\u201372.","journal-title":"Dtsch Arztebl Int"},{"key":"1713_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21051690.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1713_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(10):1616\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1713_CR5","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/bjd.13932","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Tha\u00e7i D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930\u20139.","journal-title":"Br J Dermatol"},{"issue":"7551","key":"1713_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature14175","volume":"521","author":"T Kopp","year":"2015","unstructured":"Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 2015;521(7551):222\u20136.","journal-title":"Nature"},{"issue":"3","key":"1713_CR7","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jaad.2013.10.043","volume":"70","author":"AA Levin","year":"2014","unstructured":"Levin AA, Gottlieb AB. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014;70(3):555\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"10091","key":"1713_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"3","key":"1713_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605\u201317.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1713_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Thaci","year":"2021","unstructured":"Thaci D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1713_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16724","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615\u201322.","journal-title":"Br J Dermatol"},{"key":"1713_CR12","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.17752","volume":"103","author":"ELM Ter Haar","year":"2023","unstructured":"Ter Haar ELM, Van den Reek J, Gaarn Du Jardin K, Barbero-Castillo A, De Jong E, Lubeek SFK. Efficacy and safety of tildrakizumab in older patients: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 244 weeks. Acta Derm Venereol. 2023;103:adv17752.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"1713_CR13","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1713_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","volume":"91","author":"K Gebauer","year":"2024","unstructured":"Gebauer K, Spelman L, Yamauchi PS, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: a multicenter, randomized, double-blind, placebo-controlled, phase 3b study. J Am Acad Dermatol. 2024;91(1):91\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1713_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2024.12.018","volume":"92","author":"HL Sofen","year":"2025","unstructured":"Sofen HL, Gebauer K, Spelman L, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2025;92(4):816\u201324.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1713_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1080\/14712598.2025.2519525","volume":"25","author":"M Megna","year":"2025","unstructured":"Megna M, Lauletta G, D\u2019Agostino M, et al. Biologics targeting IL-23 in moderate-to-severe psoriasis: lessons learned from real-world use. Expert Opin Biol Ther. 2025;25(7):711\u201329.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1713_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2023","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2023;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1713_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.15878","volume":"34","author":"M Masson Regnault","year":"2020","unstructured":"Masson Regnault M, Casta\u00f1eda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase III clinical studies? Cohort study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34(2):293\u2013300.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1713_CR19","unstructured":"von Kiedrowski R, Dirschka T, Kr\u00e4hn-Senftleben G, et al. Empfehlungen f\u00fcr die ambulante Versorgung von Psoriasis vulgaris. Aktualisierter praxisnaher Behandlungspfad. 2019. https:\/\/onkoderm.de\/wp-content\/uploads\/2022\/07\/onkoderm_Behandlungspfad_Psoriasis_2019_E3.pdf. Accessed 8 Jan 2026."},{"issue":"1","key":"1713_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2438803","volume":"36","author":"S St\u00e4nder","year":"2025","unstructured":"St\u00e4nder S, Tha\u00e7i D. Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe. J Dermatol Treat. 2025;36(1):2438803.","journal-title":"J Dermatol Treat"},{"issue":"9","key":"1713_CR21","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s13555-022-00789-9","volume":"12","author":"G Kokolakis","year":"2022","unstructured":"Kokolakis G, Kreis G, Falqu\u00e9s M, Aparici M, Sondermann W. High tolerability, favorable safety, and subjects\u2019 preference for a single 200 mg\/2 mL tildrakizumab injection: a phase I, open-label, randomized crossover trial in healthy volunteers. Dermatol Ther (Heidelb). 2022;12(9):2135\u201344.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1713_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000519924","volume":"238","author":"KA Drerup","year":"2022","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615\u20139.","journal-title":"Dermatology"},{"issue":"6","key":"1713_CR23","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.","journal-title":"Dermatol Ther"},{"key":"1713_CR24","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/CCID.S402183","volume":"16","author":"A Ruggiero","year":"2023","unstructured":"Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Investig Dermatol. 2023;16:529\u201336.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"1713_CR25","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s13555-024-01252-7","volume":"14","author":"M Burlando","year":"2024","unstructured":"Burlando M, Salvi I, Parodi A, Cozzani E. A 3-year experience with tildrakizumab treatment for patients with plaque psoriasis in clinical practice. Dermatol Ther (Heidelb). 2024;14(9):2645\u201352.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"Suppl 1(Suppl 1","key":"1713_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.19296","volume":"39","author":"S Gerdes","year":"2025","unstructured":"Gerdes S, Hoffmann M, Asadullah K, et al. Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: week 104 results from the non-interventional, prospective, German multicentre PERSIST study. J Eur Acad Dermatol Venereol. 2025;39(Suppl 1(Suppl 1)):38\u201349.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1713_CR27","unstructured":"Competenzzentrum Versorgungsforschung in der Dermatologie. The German Psoriasis-Registry. Registration frequencies. https:\/\/www.psobest.de\/en\/registration-frequencies-2\/. Accessed 16 Oct 2025."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01713-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01713-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:18:26Z","timestamp":1779949106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01713-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1713"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01713-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Athanasios Tsianakas: AT received honoraria for speaker and advisor activities from Almirall. AT acted as investigator in the presented TILOT trial. Nina Magnolo: speaker\u2019s\/advisor\u2019s honoraria from Abbvie, Almirall, Amgen, BMS, B\u00f6hringer-Ingelheim, Celltrion, Dr. Wolff, Janssen-Cilag, La Roche-Posay, Leo Pharma, Lilly, Novartis, Pfizer, Sanofi and UCB. Afra Kempf and Astrid Kirsch are employees of Almirall Hermal GmbH. Frank Andersohn: fees or honoraria from: Abbott, Almirall, AstraZeneca, Berlin Chemie, Boehringer Ingelheim, InGef, Lundbeck, Novartis, Novo Nordisk and Xcenda. Georgios Kokolakis reports consulting fees from Bayer; payment or honoraria from AbbVie, Abbott, Actelion Pharmaceuticals, Amgen, Basilea Pharmaceutica, Biogen IDEC, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Parexel, Pfizer and UCB Pharma; support for attending meetings or travel from AbbVie, Abbott, Amgen, Basilea Pharmaceutica, Celgene, Janssen-Cilag, LEO Pharma, MSD, Novartis, Pfizer, Sanofi and UCB Pharma; and serving on a data safety monitoring board or advisory board for AbbVie, Abbott, Amgen, Basilea Pharmaceutica, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, LEO Pharma, Eli Lilly, Novartis, Takeda and UCB Pharma. Dennis Niebel: travel reimbursements, speaker\u2019s\/advisor\u2019s honoraria or research funding from: Abbvie, Almirall, Apogee Therapeutics, AstraZeneca, Boehringer Ingelheim, Celltrion, Bristol Myer Squibb, Eli Lilly, GlaxoSmithKline, Hexal AG\/Sandoz Group, Incyte, Johnson and Johnson, Kyowa Kirin, LEO Pharma, L\u2019Oreal, MSD, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The present meta-analysis included two completed and two ongoing non-interventional studies. All were designed, implemented and performed in accordance with the applicable legislation on non-interventional studies and the ethical principles set forth in the Declaration of Helsinki and the guidelines on good pharmacovigilance practices. ICH-GCP guidelines were followed whenever possible. The studies included in the meta-analysis received approval from their respective ethics committees (TILOT: ethics committee of the medical council Niedersachsen (Bo\/40\/2018), TiGER: ethics committee of the medical council Westfalen-Lippe and the Westphalian Wilhelms-University (2021-779-f-S), TIL-TWO: ethics committee of the University Regensburg (22-3193-101), TIL-SENIOR: ethics committee of the Charit\u00e9, Berlin (EA4\/031\/23)). No diagnostic or therapeutic procedures beyond routine clinical practice were required, and treatment routine was not altered by these studies. All patients provided their written informed consent prior to participating in the respective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}